Singapore: Bristol-Myers Squibb (BMS) has entered into a multi-year strategic partnership with Tsinghua University, Beijing, China. According to the agreement, BMS will provide grants to the School of Life Sciences, Tsinghua University, in order to identify and validate novel targets in oncology and immunoscience. The collaboration will also focus on structural biology research, mapping of three dimensional proteins of biological molecular targets that could serve as the basis for future drug discovery projects.

Dr Francis Cuss, senior vice president, research while speaking in this regard said, "This is Bristol-Myers Squibb's first discovery collaboration in China and is an example of the company's deepening commitment to the country. We are delighted to be working with Tsinghua University, a world-renowned and highly esteemed research-based academic institution with expertise in target identification and structural biology that will support the discovery of new medicines to fight serious diseases in China and around the world."

Professor Kejun Kang, vice president, Tsinghua University, said, "On April 22, 1911, almost 101 years ago, Tsinghua University was founded. We have committed ourselves to working with the finest institutions and enterprises to jointly conduct cutting-edge research. In that spirit, Tsinghua University's School of Life Sciences is building a strategic partnership with Bristol-Myers Squibb. I strongly believe that future cooperation between Tsinghua University and Bristol-Myers Squibb will bring about further-reaching consequences to both organizations and I wish every success in this cooperation."